CTI BioPharma surges on plan to submit marketing application for cancer drug

CTI Biopharma

29/09/2020 23:19

** Biopharmaceutical co's shares  CTIC.O  jump ~203% to
$2.13 in extended trade 
    ** Company to submit a marketing application for the
accelerated approval of pacritinib, as a treatment for a type of
bone marrow cancer in patients with severe low level of blood
platelets  urn:newsml:reuters.com:*:nPn8JvCN3a
    ** CTC says the U.S. Food and Drug Administration has agreed
to a rolling marketing application submission, which is expected
to commence within a few weeks  urn:newsml:reuters.com:*:nPn8JvCN3a
    ** Submission of New Drug Application to the FDA is
anticipated in Q1 of 2021 
    ** The ongoing Phase 3 PACIFICA trial is expected to be
completed as a post-marketing commitment
    ** CTIC is down 22.5% YTD

 (Reporting by Arunima Kumar in Bengaluru)
 ((Arunima.Kumar@thomsonreuters.com))